TG Therapeutics reports five-year analysis shows BRIUMVI lowers disability progression risk vs Roche’s Ocrevus and Novartis’ Kesimpta
TGTX•TG Therapeutics announced a peer-reviewed five-year comparative analysis suggesting BRIUMVI may reduce long-term disability worsening risk versus Ocrevus or Kesimpta in cross-trial comparisons. The exploratory analysis also indicated lower relapse activity over time versus Ocrevus.
1. Five-year analysis
TG Therapeutics announced publication of a five-year comparative analysis of BRIUMVI and rival anti-CD20 drugs in relapsing multiple sclerosis. The exploratory cross-trial comparisons suggested lower long-term disability worsening risk versus Ocrevus or Kesimpta and lower relapse activity over time versus Ocrevus; the findings were based on adjusted comparisons, not head-to-head testing.
